Diagnostic and Prognostic Value of Soluble Syndecan-1 in Pleural Malignancies

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Mundt, Filip ^a   Heidari Hamedani, Ghazal ^a   Nilsonne, Gustav ^b,c   Metintas, Muzaffer ^d   Hjerpe, Anders ^a   Dobra, Katalin ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c STOCKHOLM UNIVERSITY   (Sweden)

^d ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPONTIN; SOLUBLE SYNDECAN 1; SYNDECAN 1; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MALIGNANT PLEURA EFFUSION; MIDDLE AGED; PLEURA CANCER; PLEURA MESOTHELIOMA; PLEURA METASTASIS; PLEURA TUMOR; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SERUM; SURVIVAL RATE; TUMOR DIFFERENTIATION; BLOOD; LUNG NEOPLASMS; MESOTHELIOMA; PATHOLOGY; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS; SYNDECAN-1; TUMOR MARKERS, BIOLOGICAL;

EID: 84935909419     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/419853     Document Type: Article

References (61)

1. C. Mortensen, R. Bhatnagar, and A. J. Edey, "Imaging the pleura, " British Journal of Hospital Medicine, vol. 73, no. 11, pp. 626-632, 2012.
2. J. Kassis, J. Klominek, and E. C. Kohn, "Tumor microenvironment: what can effusions teach us?" Diagnostic Cytopathology, vol. 33, no. 5, pp. 316-319, 2005.
3. S. Bielsa, A. Salud, M. Martinez et al., "Prognostic significance of pleural fluid data in patients with malignant effusion, " European Journal of Internal Medicine, vol. 19, no. 5, pp. 334-339, 2008.
4. I. S. Fentiman, R. Millis, S. Sexton, and J. L. Hayward, "Pleural effusion in breast cancer: a review of 105 cases, " Cancer, vol. 47, no. 8, pp. 2087-2092, 1981.
5. H. Nasser and T. J. Kuntzman, "Pleural effusion in women with a known adenocarcinoma: the role of immunostains in uncovering another hidden primary tumor, " Acta Cytologica, vol. 55, no. 5, pp. 438-444, 2011.
6. G. Lombardi, F. Zustovich, M. O. Nicoletto, M. Donach, G. Artioli, and D. Pastorelli, "Diagnosis and treatment of malignant pleural effusion: a systematic literature review and new approaches, " American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 33, no. 4, pp. 420-423, 2010.
7. N. Usami, S. Iwano, and K. Yokoi, "Solitary fibrous tumor of the pleura: evaluation of the origin with 3D CT angiography, " Journal ofThoracic Oncology, vol. 2, no. 12, pp. 1124-1125, 2007.
8. V. B. Antony, R. Loddenkemper, P. Astoul et al., "Management of malignant pleural effusions, " European Respiratory Journal, vol. 18, no. 2, pp. 402-419, 2001.
9. R. Loddenkemper, "Thoracoscopy-state of the art, " European Respiratory Journal, vol. 11, no. 1, pp. 213-221, 1998.
10. P. Y. Wai and P. C. Kuo, "The role of osteopontin in tumor metastasis, " Journal of Surgical Research, vol. 121, no. 2, pp. 228-241, 2004.
11. H. I. Pass, D. Lott, F. Lonardo et al., "Asbestos exposure, pleural mesothelioma, and serumosteopontin levels, "TheNew England Journal of Medicine, vol. 353, no. 15, pp. 1564-1573, 2005.
12. P. Y. Wai and P. C. Kuo, "Osteopontin: regulation in tumor metastasis, " Cancer and Metastasis Reviews, vol. 27, no. 1, pp. 103-118, 2008.
13. L. A. Shevde, S. Das, D. W. Clark, and R. S. Samant, "Osteopontin: an effector and an effect of tumor metastasis, " Current Molecular Medicine, vol. 10, no. 1, pp. 71-81, 2010.
14. G. F. Weber, "The cancer biomarker osteopontin: combination with other markers, " Cancer Genomics and Proteomics, vol. 8, no. 6, pp. 263-288, 2011.
15. S. Van Der Bij, E. Schaake, H. Koffijberg, J. A. Burgers, B. A. J. M. DeMol, andK. G. M. Moons, "Markers for the non-invasive diagnosis ofmesothelioma: a systematic review, " British Journal of Cancer, vol. 104, no. 8, pp. 1325-1333, 2011.
16. S. C. Kao, G. Reid, N. van Zandwijk, D. W. Henderson, and S. Klebe, "Molecular biomarkers inmalignantmesothelioma: state of the art, " Pathology, vol. 43, no. 3, pp. 201-212, 2011.
17. K. Hollevoet, K. Nackaerts, R. Gosselin et al., "Solublemesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma, " Journal ofThoracic Oncology, vol. 6, no. 11, pp. 1930-1937, 2011.
18. D. X. Cao, Z. Li, X. Jiang et al., "Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers, " World Journal of Gastroenterology, vol. 18, no. 30, pp. 3923-3930, 2012.
19. A. N. Husain, T. Colby, N. Ordonez et al., "Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group, " Archives of Pathology and Laboratory Medicine, vol. 137, no. 5, pp. 647-667, 2013.
20. P. G. Chu, D. A. Arber, and L. M. Weiss, "Expression of T/NKcell and plasma cell antigens in nonhematopoietic epithelioid neoplasms: an immunohistochemical study of 447 cases, " The American Journal of Clinical Pathology, vol. 120, no. 1, pp. 64-70, 2003.
21. A. Saqi, S. S. Yun, G. H. Yu et al., "Utility of CD138 (Syndecan-1) in distinguishing carcinomas from mesotheliomas, " Diagnostic Cytopathology, vol. 33, no. 2, pp. 65-70, 2005.
22. F. P. OConnell, J. L. Pinkus, and G. S. Pinkus, "CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms, " American Journal of Clinical Pathology, vol. 121, no. 2, pp. 254-263, 2004.
23. A. C. Rapraeger, B. J. Ell, M. Roy et al., "Vascular endothelialcadherin stimulates syndecan-1-coupled insulin-like growth factor-1 receptor and cross-talk between αvβ3 integrin and vascular endothelial growth factor receptor 2 at the onset of endothelial cell dissemination during angiogenesis, " FEBS Journal, vol. 280, no. 10, pp. 2194-2206, 2013.
24. K. J. McQuade and A. C. Rapraeger, "Syndecan-1 transmembrane and extracellular domains have unique and distinct roles in cell spreading, "The Journal of Biological Chemistry, vol. 278, no. 47, pp. 46607-46615, 2003.
25. D. M. Beauvais, B. J. Ell, A. R. McWhorter, and A. C. Rapraeger, "Syndecan-1 regulates αvβ3 and αvβ 5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor, " Journal of Experimental Medicine, vol. 206, no. 3, pp. 691-705, 2009.
26. D. J. Carey, "Syndecans: multifunctional cell-surface coreceptors, " Biochemical Journal, vol. 327, part 1, pp. 1-16, 1997.
27. S. Brule, N. Charnaux, A. Sutton et al., "The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9, " Glycobiology, vol. 16, no. 6, pp. 488-501, 2006.
28. G. Su, S. A. Blaine, D. Qiao, and A. Friedl, "Membrane type 1 matrix metalloproteinase-mediated stromal syndecan-1 shedding stimulates breast carcinoma cell proliferation, " Cancer Research, vol. 68, no. 22, pp. 9558-9565, 2008.
29. R. D. Sanderson, "Heparan sulfate proteoglycans in invasion and metastasis, " Seminars in Cell and Developmental Biology, vol. 12, no. 2, pp. 89-98, 2001.
30. V. C. Ramani, A. Purushothaman, M. D. Stewart et al., "The heparanase/syndecan-1 axis in cancer: mechanisms and therapies," FEBS Journal, vol. 280, no. 10, pp. 22942306, 2013.
31. E. Garusi, S. Rossi, and R. Perris, "Antithetic roles of proteoglycans in cancer, " Cellular and Molecular Life Sciences, vol. 69, no. 4, pp. 553-579, 2012.
32. S. Kumar-Singh, W. Jacobs, K. Dhaene et al., "Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome, " The Journal of Pathology, vol. 186, no. 3, pp. 300-305, 1998.
33. T. L. Nguyen, W. E. Grizzle, K. Zhang, O. Hameed, G. P. Siegal, and S. Wei, "Syndecan-1 overexpression is associated with nonluminal subtypes and poor prognosis in advanced breast cancer, " American Journal of Clinical Pathology, vol. 140, no. 4, pp. 468-474, 2013.
34. C. Seidel, A. Sundan, M. Hjorth et al., "Serumsyndecan-1: a new independent prognostic marker in multiple myeloma, " Blood, vol. 95, no. 2, pp. 388-392, 2000.
35. H. Joensuu, A. Anttonen, M. Eriksson et al., "Soluble syndecan and serum basic fibroblast growth factor are new prognostic factors in lung cancer, " Cancer Research, vol. 62, no. 18, pp. 5210-5217, 2002.
36. M. Metintas, G. Hillerdal, S. Metintas, and P. Dumortier, "Endemic malignant mesothelioma: exposure to erionite is more important than genetic factors, " Archives of Environmental and Occupational Health, vol. 65, no. 2, pp. 86-93, 2010.
37. F. Mundt, G. Nilsonne, S. Arslan et al., "Hyaluronan and NERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma, " PLoS ONE, vol. 8, no. 8, Article ID e72030, 2013.
38. N. Hirayama, C. Tabata, R. Tabata et al., "Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma, " Respiratory Medicine, vol. 105, no. 1, pp. 137-142, 2011.
39. M. J. Pencina, S. DAgostino, and R. S. Vasan, "Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond, " Statistics in Medicine, vol. 27, no. 2, pp. 157-172, 2008.
40. E. W. Steyerberg, A. J. Vickers, N. R. Cook et al., "Assessing the performance of prediction models: a framework for traditional and novel measures, " Epidemiology, vol. 21, no. 1, pp. 128-138, 2010.
41. D. W. Hosmer, T. Hosmer, S. Le Cessie, and S. Lemeshow, "A comparison of goodness-of-fit tests for the logistic regression model, " Statistics in Medicine, vol. 16, no. 9, pp. 965-980, 1997.
42. J. Budczies, F. Klauschen, B. V. Sinn et al., "Cutoff finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization, " PLoS ONE, vol. 7, no. 12, Article ID e51862, 2012.
43. A. Anttonen, P. Heikkila, M. Kajanti, M. Jalkanen, and H. Joensuu, "High syndecan-1 expression is associated with favourable outcome in squamous cell lung carcinoma treated with radical surgery, " Lung Cancer, vol. 32, no. 3, pp. 297-305, 2001.
44. M. Fujiya, J. Watari, T. Ashida et al., "Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer, " Japanese Journal of Cancer Research, vol. 92, no. 10, pp. 1074-1081, 2001.
45. A. C. Rapraeger, "Synstatin: A selective inhibitor of the syndecan-1-coupled IGF1R-αvβ3 integrin complex in tumorigenesis and angiogenesis, " FEBS Journal, vol. 280, no. 10, pp. 2207-2215, 2013.
46. S. C. Dong, J. Kim, H. Ryu et al., "Syndecan-1, a key regulator of cell viability in endometrial cancer, " International Journal of Cancer, vol. 121, no. 4, pp. 741-750, 2007.
47. Y. H. Teng, R. S. Aquino, and P. W. Park, "Molecular functions of syndecan-1 in disease, "Matrix Biology, vol. 31, no. 1, pp. 3-16, 2012.
48. R. Lovell, J. A. Dunn, G. Begum et al., "Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival, " British Journal of Haematology, vol. 130, no. 4, pp. 542-548, 2005.
49. F. Zong, E. Fthenou, J. Castro et al., "Effect of syndecan-1 overexpression on mesenchymal tumour cell proliferation with focus on different functional domains, " Cell Proliferation, vol. 43, no. 1, pp. 29-40, 2010.
50. B. Grigoriu, B. Chahine, F. Zerimech et al., "Serum mesothelin has a higher diagnostic utility than hyaluronic acid inmalignant mesothelioma, " Clinical Biochemistry, vol. 42, no. 10-11, pp. 1046-1050, 2009.
51. C. E. Hooper, A. J. Morley, P. Virgo, J. E. Harvey, B. Kahan, and N. A. Maskell, "A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions, " European Respiratory Journal, vol. 41, no. 1, pp. 18-24, 2013.
52. M. L. Fitzgerald, Z. Wang, P. W. Park, G. Murphy, and M. Bernfield, "Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase, " Journal of Cell Biology, vol. 148, no. 4, pp. 811-824, 2000.
53. M. Bernfield, M. Gotte, P. W. Park et al., "Functions of cell surface heparan sulfate proteoglycans, " Annual Review of Biochemistry, vol. 68, pp. 729-777, 1999.
54. M. Gotte, "Syndecans in inflammation, " TheFASEB Journal, vol. 17, no. 6, pp. 575-591, 2003.
55. K. Ding, M. Lopez-Burks, J. A. Sanchez-Duran, M. Korc, and A. D. Lander, "Growth factor-induced shedding of syndecan confers glypican-1 dependence on mitogenic responses of cancer cells, " Journal of Cell Biology, vol. 171, no. 4, pp. 729-738, 2005.
56. A. Purushothaman, L. Chen, Y. Yang, and R. D. Sanderson, "Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma, " Journal of Biological Chemistry, vol. 283, no. 47, pp. 32628-32636, 2008.
57. J. Oh, J. Kim, H. Ahn et al., "Syndecan-1 enhances the endometrial cancer invasion by modulating matrix metalloproteinase expression through nuclear factor κB, " Gynecologic Oncology, vol. 114, no. 3, pp. 509-515, 2009.
58. C. A. Thompson, A. Purushothaman, V. C. Ramani, I. Vlodavsky, and R. D. Sanderson, "Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes, " Journal of Biological Chemistry, vol. 288, no. 14, pp. 10093-10099, 2013.
59. V. C. Ramani and R. D. Sanderson, "Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapse," Matrix Biology: Journal of the International Society for Matrix Biology, vol. 35, pp. 215222, 2013.
60. A. Anttonen, S. Leppa, T. Ruotsalainen, H. Alfthan, K. Mattson, and H. Joensuu, "Pretreatment serum syndecan-1 levels and outcome in small cell lung cancer patients treated with platinum-based chemotherapy, " Lung Cancer, vol. 41, no. 2, pp. 171-177, 2003.
61. A. Anttonen, S. Leppa, P. Heikkila, R. Grenman, andH. Joensuu, "Effect of treatment of larynx and hypopharynx carcinomas on serum syndecan-1 concentrations, " Journal of Cancer Research and Clinical Oncology, vol. 132, no. 7, pp. 451-457, 2006.